Business & Finance
Global Access Diagnostics Formed to Expand Affordable Access to Advanced Rapid Diagnostic Technologies
16 June 2022 - - UK-based Global Access Health, a social enterprise focused on providing affordable medical products for global health, has formally introduced its first portfolio company, Global Access Diagnostics, the company said.

GADx has been created to address gaps in the global provision of diagnostics with a focus on expanding affordable access to quality tests.

The company combines expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics.

GADx is a social enterprise where all surplus is re-invested to deliver quality and affordable diagnostics to those in most need.

This includes transferring diagnostic technology to low-middle income countries, delivering tests such as COVID-19 to communities in need, and developing tests for neglected diseases such as dengue, bilharzia, and river blindness.

It is a unique initiative set up and supported by GAH which was formed in 2021 by a group of philanthropic funds and investors led by the Soros Economic Development Fund, with support from the Bill and Melinda Gates Foundation.

Through this transaction, the group acquired Mologic and GAD to harness industry-leading expertise in developing and manufacture of rapid diagnostic technologies.

Combining this expertise under the GADx single brand advances the organisation's philanthropic goals to maximise its contribution to global healthcare.

In addition to its product portfolio, GADx offers world-leading expertise for contract research and development, as well as helping companies to scale-up manufacturing (prototyping to pilot-scale) with capacity to produce over 2m test per day, and then facilitate local manufacturing and/or onward distribution throughout the world.

Through decentralized research, development, and manufacturing in and for the Global South, GADx aims to address gaps in the provision of global diagnostics, in regions that profit-focused business has failed to address.